Big Three PBM Specialty Pharmacy Operations

Overview

The FTC documented that PBM-owned pharmacies are reimbursed at higher rates than independents on nearly every specialty generic drug examined, and that a disproportionate share of prescriptions marked up >$1,000 flows to affiliated dispensing operations. This is the defining competitive dynamic in specialty pharmacy — and the central tension for manufacturers choosing distribution partners.

Metric	CVS Specialty	Accredo	OptumRx Specialty
Parent	CVS Health	Cigna/Evernorth	UnitedHealth Group
PBM	CVS Caremark	Express Scripts	OptumRx
Est. SP Revenue (2023)	$73.3B	$59.5B	~$46.5B
Private-Label Biosimilar	Cordavis	Quallent Pharmaceuticals	Nuvaila
Copay Maximizer Program	PrudentRx	SaveOnSP	Specialty accumulator programs

CVS Specialty / CVS Caremark

Scale and Dispensing Model

CVS does not break out specialty pharmacy as a standalone revenue line. The closest proxy is Mail & Specialty within the Health Services segment: $70.9B in FY2024 (+4.2% YoY), growing to $79.3B in FY2025 (+11.9%). CVS Caremark manages ~87 million plan members.

CVS Specialty operates across three dispensing channels: centralized specialty mail-order (primary), Specialty Connect retail pickup at ~9,000 CVS locations (dispensed centrally but picked up in-store, yielding a 13-point adherence improvement), and 23 dedicated walk-in specialty pharmacies near major medical hubs. Infusion services operate through Coram CVS Specialty Infusion Services. Specialty Expedite — an EHR-connected prior authorization tool — reduces therapy start from ~3 weeks to as few as 3 days, with >50% of connected-office prescriptions processed without additional outreach.

Cordavis Biosimilar Subsidiary

Cordavis, launched August 2023, is CVS Health’s private-label biosimilar subsidiary. It does not manufacture biosimilars but enters commercial agreements with manufacturers to relabel products for CVS Caremark formularies. This represents a third layer of vertical capture — CVS now profits at the commercialization, PBM, and dispensing levels simultaneously.

Three confirmed products: Hyrimoz (adalimumab, with Sandoz — brand Humira excluded from Caremark formularies, 95% member transition, $1.5B gross savings claimed), Pyzchiva (ustekinumab, with Samsung Bioepis), and Ospomyv (denosumab, with Samsung Bioepis, replacing Prolia at >50% lower cost starting April 2026). CVS has blocked third-party reporting of Cordavis sales data since early 2025, making external valuation impossible.

Manufacturer Hub Interactions

CVS Specialty cooperates with external hubs (ConnectiveRx, EVERSANA, Lash Group) for limited distribution drug (LDD) dispensing and copay enrollment routing. Tensions emerge in three areas: (1) exclusive specialty network designs that reject non-CVS pharmacy fills; (2) biosimilar mandates that displace brand manufacturer hub programs entirely — when Caremark mandates Cordavis Hyrimoz, AbbVie’s hub program becomes irrelevant; and (3) PrudentRx, CVS Caremark’s copay maximizer, which partially supplants hub functions by managing manufacturer copay card enrollment directly. See Copay Accumulators and Maximizers for the mechanics and manufacturer impact.

CVS sold its own hub business (RxCrossroads) to McKesson in 2017, creating a clean competitive separation between its PBM/SP operations and the hub vendor ecosystem. A critical signal of CVS Specialty’s standalone value: both Tyson Foods and Blue Shield of California dropped Caremark as PBM but retained CVS Specialty for dispensing — demonstrating competitive stickiness independent of the PBM relationship.

Strategic Position (2024-2026)

CEO David Joyner (appointed October 2024) is a PBM/specialty veteran refocusing on core pharmacy operations. Oak Street Health saw 16 clinics closed and a $5.7B impairment charge. Omnicare (LTC pharmacy) filed Chapter 11 bankruptcy in September 2025 after a $949M federal fraud judgment. The non-pharmacy diversification strategy is clearly unwinding, with specialty pharmacy and PBM operations emerging as the strategic core.

Accredo / Express Scripts / Evernorth

Scale and Clinical Model

Accredo revenue flows through Evernorth’s Specialty and Care Services segment: $90.3B in adjusted revenue for FY2024 (+18% YoY) generating $3.4B in pre-tax adjusted income. Drug Channels estimated Accredo’s standalone 2023 prescription revenues at $59.5B. In 2024, Accredo delivered 8 million+ prescriptions to 1 million+ patients with 3.1 million clinical interactions. Accredo holds ~25% pharmacy benefit specialty market share and relationships with all 25 top U.S. health plans.

Accredo operates 15 condition-specific Therapeutic Resource Centers (TRCs) covering asthma, blood disorders, CF, endocrine, fertility, hepatology, HIV, immune/complex conditions, MS/neuro, oncology, pulmonary, rare disease, RA/inflammatory, select specialty, and transplant. Clinical staffing includes 500 pharmacists and 600+ nurses/advocates across 28 care delivery sites with 4 sterile compounding clean rooms. Key programs include Pathwell Specialty (site-of-care optimization, ~50% of eligible patients transitioned to home infusion) and GeneAXS (gene therapy access team). The RA&I TRC model produced 12% fewer ER visits, 22% fewer inpatient admissions, and 8% lower medical costs.

CuraScript SD Relationship

CuraScript SD (specialty distributor, direct-to-provider via buy-and-bill) and Accredo (dispensing pharmacy, direct-to-patient) are separate legal entities under Evernorth. Together they cover both the pharmacy benefit channel (~$240B addressable, ~~25% share) and medical benefit channel (~~$160B addressable, ~6% share). CuraScript maintains 200,000+ sq. ft. of controlled distribution space with 99.9% order accuracy. See Buy-and-Bill Reimbursement Model for how the medical benefit channel works.

SaveOnSP and Copay Dynamics

Accredo coordinated $2.8 billion in manufacturer copay assistance in 2024, with nearly half of all patients receiving support. The more consequential dynamic is SaveOnSP, Express Scripts’ copay maximizer. Plans reclassify targeted specialty drugs as non-essential health benefits, copays are artificially inflated to drain manufacturer assistance funds, and savings flow to plan sponsors rather than patients.

In December 2024, a lung cancer patient filed Gurwitch v. SaveOnSP — an ERISA/RICO class action alleging Accredo, Express Scripts, and SaveOnSP “purloined hundreds of millions, if not billions, of dollars in funding meant to help patients.” The February 2026 FTC consent order with Express Scripts directly constrains these practices, requiring member out-of-pocket costs be based on net drug cost rather than list price by 2027-2028.

Strategic Moves (2024-2026)

Four transformative developments: (1) TRICARE specialty mandate — Accredo became exclusive specialty pharmacy for TRICARE Home Delivery (March 2024), adding access to ~9.5 million military beneficiaries. (2) $3.5B investment in Shields Health Solutions (September 2025), giving Evernorth a stake in hospital-based specialty pharmacies across 80+ health systems and 1,000+ hospitals — a third dispensing channel alongside Accredo (mail) and CuraScript SD (provider). (3) Evernorth Care Group divested to HonorHealth (January 2026), signaling exit from primary care to focus on pharmacy services. (4) FTC consent order requiring elimination of spread pricing and list-price-based OOP by 2027-2028 under a 3-year compliance monitor. Brian Evanko succeeds David Cordani as CEO effective July 2026.

OptumRx Specialty / UnitedHealth Group

Scale and Multi-Brand Portfolio

OptumRx is the standout performer within a troubled UHG enterprise. FY2025 revenue reached $154.7B (+16% YoY) with $7.2B in operating earnings (+23%), managing $188B in pharmaceutical spending including ~$87B in specialty pharmaceutical spending — the first disclosed specialty-specific figure. Drug Channels estimated OptumRx dispensing revenues at ~$46.5B in 2024. OptumRx serves 62+ million consumers through ~64,000 contracted retail pharmacies and five owned pharmacy brands.

The multi-brand portfolio includes Optum Specialty Pharmacy (200+ conditions), Optum Frontier Therapies (rare disease/gene therapy), Optum Infusion Pharmacy, Optum Home Delivery (~625K 30-day scripts shipped daily), and Genoa Healthcare (~750 behavioral health locations across 47 states). A 2025 merger of Genoa with PharmScript (long-term care pharmacy) expanded the combined entity to 764 pharmacies, 44 million prescriptions annually, and $7.5B in revenue. Total LDD access exceeds 200 drugs, with 12 new LDD awards in 2025.

Vertical Integration Conflict

The UnitedHealthcare (49.8M members, $344.9B revenue) to OptumRx (PBM) to OptumRx Specialty (dispensing) chain creates four-point revenue capture per specialty drug transaction. In 2025, 60% of OptumRx revenues ($96.9B) came from affiliated UnitedHealthcare transactions — the starkest indicator of captive volume magnitude.

Manufacturer concerns center on: (1) formulary exclusion as negotiating leverage — the FTC found PBMs “threatened to exclude certain drugs from their formularies to extract higher rebates”; (2) Nuvaila private-label biosimilar creating a direct conflict where the formulary gatekeeper holds financial interest in the competing product; (3) white bagging mandates on 100+ specialty/oncology drugs transferring dispensing margin from providers to OptumRx-owned pharmacies (only 12 states ban this practice); and (4) Optum Insight selling analytics derived from 200M+ claims records back to the same manufacturers whose formulary negotiations OptumRx controls. See Gross-to-Net Dynamics for how rebate negotiations interact with these vertical dynamics.

Regulatory and Legal Exposure (2024-2026)

UHG faces an unprecedented convergence of crises. UnitedHealthcare CEO Brian Thompson was killed on December 4, 2024, triggering public backlash that forced nearly 50 insurers to pledge prior authorization reform. CEO Andrew Witty resigned May 2025, replaced by returning former CEO Stephen Hemsley.

Three simultaneous federal investigations are active: DOJ criminal/civil probe into Medicare Advantage billing (disclosed July 2025); DOJ criminal investigation of OptumRx prescription management services (disclosed August 2025) — the first known criminal probe directly targeting OptumRx operations; and the FTC administrative action over insulin rebating practices. Despite this, OptumRx guided for 800+ new client relationships in 2026-2027 and 100% rebate passthrough by 2028.

LDD Network Competition

Drug Channels tracked 382 drugs in manufacturer-defined limited/exclusive distribution networks as of January 2025. Network structure: 34% exclusive (1 pharmacy), 34% limited (2-4), 20% small (5-10), 12% larger (11-25). In broader limited networks, CVS Caremark and Accredo together access ~50% of drugs. However, in exclusive networks, PBM-affiliated pharmacies hold only ~25% of products — independents like PANTHERx Rare (12%) and McKesson Biologics (14%) dominate ultra-specialized rare disease dispensing.

Manufacturers face implicit pressure to include PBM-owned SPs in broader networks given formulary leverage, but increasingly choose specialized independents for highest-touch rare and gene therapies where clinical depth outweighs distribution scale. Even beyond manufacturer LDD selections, PBMs narrow networks further by requiring patients to use preferred affiliated pharmacies regardless of the manufacturer’s intended distribution design. See Hub Services Overview for how LDD and hub program design intersect.

Competitive Dynamics with Independent Specialty Pharmacies

The FTC’s definitive finding: Big 3 affiliated pharmacies received 68% of specialty drug dispensing revenue in 2023, up from 54% in 2016. The FTC documented active steering — not passive routing — of the most profitable prescriptions to affiliated pharmacies, generating $7.3B in excess dispensing revenue above NADAC on specialty generics from 2017-2022 at a 42% CAGR.

Independent SPs compete on clinical specialization and manufacturer relationships rather than volume. Hospital-owned specialty pharmacies (27% of accredited SPs, up from 15% in 2017) represent the most credible competitive threat to PBM-owned SPs, particularly as Evernorth’s $3.5B Shields investment validates hospital-based dispensing as a growth channel.

PBMs use accreditation (URAC, ACHC) as a contractual prerequisite for network participation while imposing additional credentialing requirements on independents that their own pharmacies effectively avoid. The specialty drug classification itself — which triggers mandatory specialty pharmacy routing — is entirely PBM-controlled. North Carolina enacted SB 203 (2025) specifically protecting URAC-accredited independents from PBM over-credentialing.

340B Specialty Dispensing

The 340B program intersects with PBM specialty operations in complex ways. Covered entities (safety-net hospitals, FQHCs, certain clinics) can access 340B ceiling prices on specialty drugs and dispense through contract pharmacies — including PBM-owned SPs. However, PBMs have increasingly restricted 340B contract pharmacy arrangements, and manufacturers have imposed their own 340B contract pharmacy limitations since 2020.

The tension: PBMs benefit from higher-priced specialty dispensing through their owned pharmacies, but 340B-eligible entities can access the same drugs at steep discounts. PBM network designs that steer patients to affiliated pharmacies can conflict with 340B covered entities’ right to use contract pharmacy arrangements. This dynamic is particularly acute in oncology, where both hospital-owned 340B pharmacies and PBM-owned specialty pharmacies compete for the same patient volume.

Regulatory Trajectory

The legislative environment represents an escalating structural threat to PBM-owned specialty pharmacy dominance:

Consolidated Appropriations Act 2026 (signed February 3, 2026): First federal PBM reform — semiannual transparency reporting on steering, Part D delinking by 2028, and any-willing-pharmacy by 2029.
Break Up Big Medicine Act (Warren-Hawley, February 2026): Would force divestiture of PBM-owned pharmacies entirely.
Arkansas Act 624 (April 2025): First state PBM pharmacy ownership ban — currently enjoined pending litigation with all three PBMs as plaintiffs.
State-level reform: At least 8 states enacted anti-steering, spread pricing, or any-willing-pharmacy laws in 2025, with California, Illinois, and Iowa among the most impactful.
FTC consent order (February 2026): Constrains Express Scripts’ copay practices by 2027-2028 under a 3-year compliance monitor.

Implications for Manufacturers

The Big 3’s dominance creates a fundamental strategic tension for pharma manufacturers. Hub vendors, copay programs, and patient services all must navigate PBM-owned specialty pharmacy dynamics:

Formulary leverage affects all downstream services: When a PBM mandates a biosimilar switch through its owned SP, the brand manufacturer’s entire hub and patient support infrastructure becomes irrelevant for that PBM’s covered lives. See Hub Services Overview and PE Consolidation in Pharma Services.
Copay maximizer programs conflict with manufacturer copay assistance: PrudentRx, SaveOnSP, and OptumRx’s accumulator programs inflate patient OOP costs to drain manufacturer copay cards faster, reducing the manufacturer’s control over the patient financial experience. See Copay Accumulators and Maximizers.
LDD design must account for PBM steering: Even when manufacturers select independent SPs for exclusive distribution, PBM benefit designs can redirect patients to affiliated pharmacies for non-LDD products or after initial fills.
Hospital-based SP is the emerging alternative: Evernorth’s Shields investment and the growth of health system-owned specialty pharmacies (27% of accredited SPs) suggest a third distribution channel that partially circumvents PBM vertical integration.

The base case outlook: Big 3 specialty pharmacy share stabilizes near 65% through 2028 as any-willing-pharmacy provisions (effective 2029) and Part D delinking (2028) slowly erode captive volume at the margins. Private-label biosimilar programs (Cordavis, Quallent, Nuvaila) become the primary margin expansion lever, replacing spread pricing revenue that regulation eliminates.